Synergistic effects of defocus-incorporated multiple segments and atropine in slowing the progression of myopia

Sci Rep. 2022 Dec 24;12(1):22311. doi: 10.1038/s41598-022-25599-z.

Abstract

Myopia is a leading cause of visual impairment in young people worldwide. It sometimes increases the risk of blindness and reduces life quality. Previous reports have revealed the treatment effects of defocus-incorporated multiple segments (DIMS) and topical atropine (ATP) on myopia control. However, no study has evaluated these two interventions together. In this retrospective study, we aimed to determine whether the combination of DIMS lenses and 0.01% ATP can slow the progression of myopia compared with DIMS lenses or single vision (SV) lenses alone. We included 107 children with myopia who were treated with DIMS and 0.01% ATP combination (DIMS + ATP group), DIMS monotherapy (DIMS group), or a control group (SV group). We compared treatment effects among three groups in axial length and myopia progression. After a 1-year follow-up, the DIMS + ATP group showed a smaller change in axial length and myopia progression than the DIMS and SV groups (P < 0.05). Hence, combination treatment with DIMS and 0.01% ATP might be a better choice for children with myopia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate
  • Adolescent
  • Atropine* / therapeutic use
  • Child
  • Disease Progression
  • Eyeglasses
  • Humans
  • Myopia* / drug therapy
  • Refraction, Ocular
  • Retrospective Studies

Substances

  • Atropine
  • Adenosine Triphosphate